Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET

Trial Profile

Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs F-18 fluorothymidine (Primary)
  • Indications Breast cancer; Male breast cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 04 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top